Dr. Vivian Chang's clinical and research interests are in understanding pediatric cancer predisposition. She uses next-generation sequencing data to comprehensively profile the mutations in patients' germline and tumor cells. The overall goals of her research are to identify known and novel genetic factors that predispose individuals to developing cancer, develop effective and personalized cancer surveillance programs, and eventually to prevent the development of cancers in this high-risk population.
Chang is the Co-Director of the Pediatric Cancer Predisposition Clinic at UCLA which provides multi-disciplinary care for pediatric patients and their families who may have a genetic predisposition to cancer. These patients are offered participation in various clinical trials and a bio-registry.
Chang VY, Basso G, Sakamoto KM, Nelson SF. Identification of somatic and germline mutations using whole exome sequencing of congenital acute lymphoblastic leukemia. BMC Cancer. 2013 Feb 4;13:55. doi: 10.1186/1471-2407-13-55.
Chang VY, Federman N, Martinez-Agosto J, Tatishchev SF, Nelson SF. Whole exome sequencing of pediatric gastric adenocarcinoma reveals an atypical presentation of Li-Fraumeni syndrome. Pediatr Blood Cancer. 2013 Apr;60(4):570-4. doi: 10.1002/pbc.24316. Epub 2012 Sep 26.
Chang VY, Quintero-Rivera F, Baldwin EE, Woo K, Martinez-Agosto JA, Fu C, Gomperts BN. B-acute lymphoblastic leukemia and cystinuria in a patient with duplication 22q11.21 detected by chromosomal microarray analysis. Pediatr Blood Cancer. 2011 Mar;56(3):470-3. doi: 10.1002/pbc.22909. Epub 2010 Nov 28.
Panosyan EH, Ikeda AK, Chang VY, Laks DR, Reeb CL, Bowles LV, Lasky JL 3rd, Moore TB. High-dose chemotherapy with autologous hematopoietic stem-cell rescue for pediatric brain tumor patients: a single institution experience from UCLA. J Transplant. 2011;2011:740673. doi: 10.1155/2011/740673. Epub 2011 Apr 14.
Eckardt MA, Chang VY, Rao NP, Federman N. Coexistence of translocation(1,19) and the Philadelphia chromosome in a child's first presentation of chronic myeloid leukemia in blast crisis treated with dasatinib. Pediatr Hematol Oncol. 2011 Nov;28(8):669-75. doi: 10.3109/08880018.2011.615048.